Certepetide

Lisata Therapeutics and GATC Health launch strategic collaboration utilizing GATC's AI-powered Multiomics Advanced Technology platform to optimize drug development and improve success rates.

The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies.

Actuate Therapeutics' elraglusib combined with gemcitabine/nab-paclitaxel (GnP) significantly improved survival rates in metastatic pancreatic cancer patients.

Lisata Therapeutics has completed enrollment in the Phase 1b/2a CENDIFOX trial evaluating certepetide combined with FOLFIRINOX-based therapies.

The FDA approved a subcutaneous formulation of atezolizumab (Tecentriq Hybreza) for various cancers, offering a more convenient administration option for patients.